A detailed history of Tower Research Capital LLC (Trc) transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,699 shares of AURA stock, worth $24,668. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,699
Previous 4,682 42.35%
Holding current value
$24,668
Previous $35,000 31.43%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.9 - $10.36 $13,682 - $20,543
-1,983 Reduced 42.35%
2,699 $24,000
Q2 2024

Aug 13, 2024

BUY
$6.81 - $7.89 $10,405 - $12,055
1,528 Added 48.45%
4,682 $35,000
Q1 2024

May 15, 2024

SELL
$7.09 - $9.24 $8,103 - $10,561
-1,143 Reduced 26.6%
3,154 $24,000
Q4 2023

Feb 13, 2024

SELL
$7.02 - $11.98 $16,195 - $27,637
-2,307 Reduced 34.93%
4,297 $38,000
Q3 2023

Nov 14, 2023

BUY
$8.97 - $12.38 $42,679 - $58,904
4,758 Added 257.75%
6,604 $59,000
Q2 2023

Aug 14, 2023

BUY
$8.51 - $13.33 $6,552 - $10,264
770 Added 71.56%
1,846 $22,000
Q1 2023

May 09, 2023

SELL
$8.88 - $12.11 $21,835 - $29,778
-2,459 Reduced 69.56%
1,076 $10,000
Q4 2022

Feb 10, 2023

BUY
$9.86 - $14.59 $22,411 - $33,163
2,273 Added 180.11%
3,535 $37,000
Q3 2022

Nov 10, 2022

SELL
$13.1 - $20.34 $35,199 - $54,653
-2,687 Reduced 68.04%
1,262 $23,000
Q2 2022

Aug 15, 2022

BUY
$12.37 - $21.86 $35,130 - $62,082
2,840 Added 256.09%
3,949 $56,000
Q1 2022

May 12, 2022

BUY
$15.94 - $23.34 $7,188 - $10,526
451 Added 68.54%
1,109 $24,000
Q4 2021

Feb 14, 2022

BUY
$14.76 - $24.89 $9,712 - $16,377
658 New
658 $11,000

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $268M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.